

European Competitiveness in Advanced Therapies: How do we Fulfill the Potential for the Benefit of Patients?

27th June | Karolinska Institute, Aula Medica, Stockholm

14:30 – 17:30 CET

Streamed live on atmpsweden.se



*In partnership with the
Swedish Presidency of
the EU Council*



Opening Session

- Ebba Busch, Swedish Minister for Energy, Business and Industry; Deputy Prime Minister
- Sara Mazur, Incoming Executive Director, Knut and Alice Wallenberg Foundation
- Jim Lund, Project Lead of ATMP 2030, ATMP Sweden
- Lucy Ellerker-Jones, Patient Advocate and Founder of the Opie Jones Foundation
- Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine

Panel discussion: The revision of the EU pharmaceutical legislation: a once in a generation opportunity to bring Europe back to a leading position in the ATMP sector

- Björn Eriksson, Director General, Swedish Medical Product Agency
- Miguel Forte, President-Elect, International Society for Cell and Gene Therapy
- Yann Le Cam, Chief Executive Officer, EURORDIS
- Anna Sandström, Senior Director, Science Policy and Relations Europe, AstraZeneca

Panel discussion: What impact will the new EU Joint Clinical Assessment have on the competitiveness of Europe in the ATMP sector?

- Niklas Hedberg, Co-chair of the EU HTA Coordination Group
- Francis Pang, Senior Vice-President Global Market Access & Geographic Expansion, Orchard Therapeutics
- Yann Le Cam, Chief Executive Officer, EURORDIS

Concluding session

- Lars Hammarström, Director Health and Life Science Division, Vinnova